FDA Suspends Ban on Juul E-cigarette Sales

Jul.13.2022
FDA Suspends Ban on Juul E-cigarette Sales
The FDA temporarily suspends ban on Juul sales for extra review, but concerns over health risks persist.

The US Food and Drug Administration (FDA) has suspended its ban on the sale of Juul Labs' e-cigarettes, stating that additional scrutiny is required for the company's marketing application. Following Juul's appeal for an urgent review of the FDA's order, the federal appeals court decided to temporarily freeze the FDA's ban a few weeks ago.


However, this once flourishing company still remains in a difficult situation: the US Food and Drug Administration has only temporarily halted the re-evaluation ban, it has not been lifted.


Juul has been in the limelight in part due to its prominent position in the e-cigarette industry. However, as the company faces potential extinction, it may become the first casualty while the rest of the e-cigarette industry comes under increasing government scrutiny.


Dr. Zubair Karim, an assistant professor in the Department of Interdisciplinary Health Sciences at Augusta University, conducted research on Juul e-cigarettes and their potential to increase the risk of blood clots and other complications in users.


According to Karim, thrombosis is the partial or complete blockage of blood vessels, whether it occurs in veins or arteries, which restricts the natural flow of blood.


According to the location of blood clot formation, there are several potential complications. The most severe issues include stroke, heart attack, and a serious respiratory condition known as pulmonary embolism. Without prompt treatment, these conditions can be life-threatening. However, by focusing on lifestyle changes such as increasing physical activity, quitting smoking, losing weight, maintaining a balanced diet, avoiding junk food, and managing other health conditions, it is possible to prevent the disease from advancing.


As a ban on Juul products looms, it could lead to a ban on other companies' electronic cigarette products.


Karim stated, "This is the first step in banning e-cigarettes, and the FDA has taken an important and bold move.


Gradually, this will pave the way for the banning of other e-cigarette products. Juul and other products are no different, but Juul is becoming increasingly popular among our younger generation. Many localities and states have recently begun implementing laws banning the use of e-cigarettes, although some states with comprehensive smoke-free laws will still allow the use of e-cigarettes in bars and restaurants while prohibiting their use in other indoor venues.


For years, electronic cigarettes and their devices have been considered a "safer" alternative to traditional cigarettes, but their flavors and packaging have attracted children, and there are renewed efforts to study their possible side effects.


Looking at the long-term effects, both smoking and vaping have similar side effects and pose serious health risks. Scientists do not fully understand the long-term impact of vaping on health, but studies show that electronic cigarettes are not a safe alternative to smoking," said Karim.


In recent years, it has been observed that electronic cigarettes are becoming increasingly popular among young people. Additionally, electronic cigarettes contain high doses of nicotine, which is known to slow the development of fetuses, children, and adolescents' brains. Furthermore, electronic cigarettes involve inhaling aerosols that contain multiple chemicals, including those used for flavoring via electronic cigarettes or other devices. Additionally, the liquid produced in electronic cigarettes can be hazardous if swallowed, inhaled, or applied topically to the skin for both adults and children.


Despite this, e-cigarettes still contain harmful chemicals such as diacetyl, carcinogens, heavy metals, volatile organic compounds, and toxic chemicals not found in traditional cigarettes. In summary, the long-term toxic effects of e-cigarette use on overall health are similar to those of traditional cigarettes.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Former cigarette smokers accounted for an estimated 54% of current e-cigarette users in Great Britain in 2025, while 26% also smoked cigarettes and 20% had never regularly smoked, according to a 2Firsts analysis of Office for National Statistics (ONS) data. Among former cigarette smokers who currently vape, approximately 81% used e-cigarettes daily, compared with about 50% of dual users. The ONS found that 33.8% of current cigarette smokers also vaped in 2025, up from 10.6% in 2014. Approximately 1.1 million adults who had never regularly smoked cigarettes used e-cigarettes, representing 2.9% of that population, compared with 0.2% in 2014. The figures highlight differences in the composition, frequency of use and long-term trends across Britain's vaping population.
DATA
Oct.14
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
According to WNCY on August 24, 2026, some independent vape retailers in Wisconsin say they have faced significant business pressure one year after new vape regulations took effect. Johnny Vapes, a retailer operating in northeast Wisconsin, said its store count fell from seven locations to four, sales declined by about 80%, and roughly 90% of its inventory was affected. Retailers said some consumers have shifted to online purchases or traveled to neighboring Michigan to buy vape products. The case highlights how local regulations can reshape retail operations, inventory management and consumer purchasing patterns.
Aug.28
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23